A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Launched by FANGYI · May 30, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PERSEVERE study is researching how local treatments for early breast cancer, like surgery and other therapies, affect women's health and daily lives over time. The main goal is to understand both the short-term and long-term side effects of these treatments, which can include feelings of tiredness, difficulty sleeping, emotional challenges, pain, or changes in heart and lung health. Researchers want to see how these side effects impact the participants' quality of life.
To be eligible for this study, participants must be women aged 18 or older who have been diagnosed with early-stage breast cancer (stages I, II, or III) and are not experiencing any spreading of the disease. They should be scheduled to receive local treatment, such as surgery or other therapies, and be willing to complete health surveys and attend follow-up visits. Participants can expect to fill out questionnaires about how they feel and undergo health checks, including tests for heart and lung function, as well as provide tissue samples from surgery. This study aims to better understand how treatment affects women and to find ways to support their recovery in the long run.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged 18 years or older
- • Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology
- • No signs of metastatic disease (cancer that has spread to other parts of the body)
- * Scheduled to receive local treatment, including:
- • Surgery
- • And/or neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy
- • Willing and able to complete health questionnaires and attend follow-up visits
- • Has given written informed consent to join the study
- Exclusion Criteria:
- • Have metastatic breast cancer or local recurrence
- • Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study
- • Are currently pregnant or breastfeeding
- • Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)
- • Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)
About Fangyi
Fangyi is a pioneering clinical trial sponsor dedicated to advancing medical research and development through innovative trial design and execution. With a focus on enhancing patient outcomes and streamlining the drug development process, Fangyi leverages cutting-edge technology and a robust network of clinical sites to ensure efficient recruitment and data integrity. Committed to ethical standards and regulatory compliance, Fangyi collaborates with leading researchers and healthcare professionals to drive forward-thinking solutions in therapeutic areas, ultimately aiming to bring safe and effective treatments to market that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Shenzhen, Guangdong, China
Taiyuan, Shanxi, China
Patients applied
Trial Officials
Yi Fang, MD
Principal Investigator
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported